How to Manage Estrogen on TRT
Your testosterone goes through a conversion process every single day, and understanding that process is what determines whether you actually need the medication most TRT clinics prescribe within the first few months.
Here is the full chain. You inject testosterone. Your body uses what it needs for all the things testosterone does, and the rest gets converted into estradiol by an enzyme called aromatase, which is something called a cytochrome P450 enzyme that works through a three-step chemical reaction to turn androgens into estrogens. That conversion happens in your adipose tissue, your brain, your bone, your liver, and your testes, though in men roughly 80 percent of circulating estradiol comes from peripheral tissue, primarily body fat, with only about 20 percent coming directly from testicular production. That is the map. Everything else in this article is about one specific part of that chain: what controls how much conversion happens, and why manipulating that variable is almost always the better first move than blocking the enzyme itself.
Most TRT protocols start with a weekly injection. Testosterone cypionate has an elimination half-life of roughly 4.5 days and a mean residence time of approximately 8.5 days, which means after a single large injection, testosterone peaks around 24 to 48 hours and then steadily declines toward a trough by day 7. Estradiol trails that by one to two days, peaking somewhere around day 3 to 4. The result is a supraphysiologic spike at the top and a sub-therapeutic dip at the bottom, and the clinic reads the lab, sees an elevated estradiol, and prescribes an aromatase inhibitor called anastrozole.
What the clinic is not asking is why the conversion was high in the first place.
Aromatase works on substrate, meaning the more raw material you give it, the more it converts. It is the same principle as a factory: the same number of workers running at full capacity will produce more output if you keep feeding them material. A large weekly injection floods the enzyme with testosterone all at once, so conversion spikes with the peak. Split that exact same weekly dose into two injections and the peak is lower each time, so each exposure gives the enzyme less substrate to work with. Split it further into daily injections, approximating the body's natural output of roughly 6 to 7 milligrams per day, and the peaks flatten considerably. Twice-weekly injection alone reduces peak-to-trough variance by approximately 30 percent compared to weekly. The total weekly dose is identical. The total estrogen production across the week may end up similar. But the peaks, and the symptoms those peaks drive, things like water retention, mood shifts, and nipple sensitivity, are largely eliminated.
That is the substrate-driven mechanism, and it is why injection frequency is the first lever to adjust before anything else.
Body fat is the second lever. Aromatase expression in adipose tissue is driven by a specific genetic promoter called I.4, and that promoter responds to glucocorticoids, inflammatory cytokines, and something called TNF-alpha, which is a signaling molecule associated with chronic inflammation. Weight gain and inflammation upregulate aromatase gene expression in male adipose tissue directly, which is why men with obesity show meaningfully higher aromatase activity than lean men. More body fat means more of the enzyme is present throughout your tissue, so the same dose of testosterone converts at a higher rate regardless of injection frequency.
Alcohol increases aromatase activity directly. Insulin resistance affects both aromatase expression and something called SHBG, which stands for sex hormone-binding globulin and functions as a carrier protein that binds testosterone and makes it unavailable for conversion, so lower SHBG from insulin resistance means more free testosterone available to aromatase at any given moment. Cortisol from chronic stress activates the same I.4 promoter that drives aromatase expression in adipose tissue. Poor sleep elevates both cortisol and inflammatory cytokines. Genetics determine your baseline CYP19A1 expression, which is the gene that codes for aromatase, so some men simply convert at a higher rate than others at the same dose.
Each of these is a dial. And the clinical habit of reaching for anastrozole before adjusting any of them is the problem.
Estrogen in men is not an excess byproduct to be managed. It is a hormone with its own set of jobs. Estradiol levels are more strongly associated with bone mineral density and bone turnover in men than testosterone levels are. Aromatase-deficient men in case studies show osteopenia and failure of bone epiphyses to close. Estrogen promotes vasodilation and protective effects on vascular smooth muscle. Brain aromatase converts testosterone to estradiol locally to support cognitive function and neuroprotection.
The Finkelstein study published in the New England Journal of Medicine in 2013 isolated this directly. Four hundred healthy men aged 20 to 50 had their natural production suppressed with goserelin, then received varying testosterone doses with or without anastrozole to block conversion. With aromatase blocked, sexual desire dropped significantly at p less than 0.001 and erectile function declined at p equals 0.022, even though testosterone was still present. Subcutaneous fat increased two to three times in the groups with suppressed estrogen. The study isolated estrogen's independent contribution by holding testosterone constant and removing only the conversion, which is the clearest demonstration available that the symptoms you started TRT to fix can return from the opposite direction when you suppress estrogen too aggressively.
The Burnett-Bowie study from 2009 ran 69 men over age 60 on 1 milligram of anastrozole daily for 12 months versus placebo. Spine bone mineral density decreased significantly in the anastrozole group at p equals 0.0014. Estradiol dropped from roughly 15 to 12 pg/mL, about a 20 percent reduction. That is measurable bone loss from a modest, seemingly controlled suppression of estrogen over one year.
The clinical trap looks like this. Weekly injection creates estrogen peaks. Anastrozole is prescribed to suppress them. Now estrogen is too low and the patient has joint pain, erectile dysfunction, depression, and is accumulating body fat. The clinic adjusts the AI dose. The patient oscillates between too high and too low while on two drugs to manage a problem that injection frequency, body composition, and lifestyle would largely resolve. Anastrozole is not FDA-approved for use in men, so every prescription is off-label, and there is no established safe range for AI dosing in a male TRT context.
If you want to know where you actually stand, the test that matters is called LC-MS/MS, which stands for liquid chromatography tandem mass spectrometry, and it is the gold standard for measuring estradiol in men because standard immunoassay tests cross-react with other steroids and routinely give inaccurate readings. For most men on standard TRT doses, a target of 20 to 35 pg/mL is reasonable. If you are running a higher dose and feeling well, 40 to 60 may be appropriate.
Work the drivers first. Increase injection frequency. Reduce body fat. Address alcohol, sleep, and stress. Retest. Most men who do this never need an aromatase inhibitor at all.
The real insight here is not that AIs are bad drugs. It is that prescribing one before you understand what is driving the conversion is treating a lab number instead of a system, and the system will keep producing that number until you address what is feeding it.
References
- Finkelstein JS, Lee H, Burnett-Bowie SA, et al. 2013. Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 36911, 1011-1022. Source
- Burnett-Bowie SM, McKay EA, Lee H, Leder BZ. 2009. Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 9412, 4785-4792. Source
- Pastuszak AW, et al. 2022. Pharmacokinetics of Testosterone Cypionate Delivered via Subcutaneous Autoinjector. Andrology. Source
- Chand AL, et al. (2015). Weight gain and inflammation regulate aromatase expression in male adipose tissue. Journal of Steroid Biochemistry and Molecular Biology.
- Bhasin S, Brito JP, Cunningham GR, et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. JCEM, 103(5), 1715-1744.
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.